Roche Diagnostics and Protedyne Sign Global Agreement
News Jan 25, 2007
Roche's LightCycler® 480 Instrument is a 96- or 384-well, plate-based quantitative PCR instrument. The LightCycler® 480 is a platform for gene-expression and mutation analysis. Based on hardware and software, the LightCycler® 480 Instrument can meet the needs of a broad range of scientific applications in genomics research.
Protedyne's Radius is a benchtop robotic system using the principles of industrial automation. Its radial design and vertical construction can provide maximum functionality that can access areas of the bench top beyond its own footprint for simple device integration.
The Radius system uses Protedyne's software that can adapts to multiple protocols and SmartTools™, easily interchangeable tools with built-in microprocessors that store tool calibration information and track performance data.
"We are committed to providing the most complete solution offering to our research customers. By integrating the Protedyne Radius's benchtop robotics with the speed, accuracy, and precision of Roche's LightCycler 480 Real-Time PCR system, we enable our research customers to focus more time on achieving their scientific discoveries," said Hans Fritton, Head of Program Management and Business Development for Roche Applied Science, a business area of Roche Diagnostics.
"Protedyne's Radius was a logical choice for the LightCycler 480 System as our technology provides the efficiency and throughput needed for highly- reproducible preparation across a broad range of scientific applications in genomics research," said Fran Tuttle, President and CEO of Protedyne.
"By combining the two systems, we can deliver to our customers exactly the throughput they are trying to achieve."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.